Boston Scientific Corporation (BSX) Maintains Analyst Ratings Amid Target Adjustments

Boston Scientific Corporation (NYSE:BSX) is one of the best medical technology stocks to invest in. On February 6, RBC Capital lowered its price target on Boston Scientific Corporation (NYSE:BSX) to $115 from $130 and maintained an Outperform rating on the shares.

RBC made the move in response to Boston Scientific’s Q4 2025 earnings share on February 4. The firm attributed the price target cut to Boston Scientific’s initial 2026 guidance and perceived weakness in its electrophysiology business, which missed quarterly consensus expectations. RBC Capital indicated that investors appear to be in a “wait and watch” mode until all electrophysiology competitors report their results.

Boston Scientific’s stock now leans heavily on the upcoming CHAMPION‑AF trial results, due March 28, which analysts see as a key event that could boost earnings.

According to the earnings results, Boston Scientific’s quarterly revenue reached $5.29 billion. This is a 12.7% organic year over year growth, and slightly surpassed consensus estimates. Adjusted EPS were $0.80 and surpassed the $0.78 Wall Street expected.

Separately, on February 6, Bernstein SocGen lowered its price target on Boston Scientific to $112 from $130 and maintained an Outperform rating. Bernstein said it trimmed the price target because Boston Scientific missed US electrophysiology sales. The sales came in at $606 million for the fourth quarter, 6% below consensus estimates. The firm also noted a 2% miss in US Watchman sales for the quarter.

Bernstein stated that there is huge upside for Boston Scientific at a 21.5x valuation. The firm cited growth opportunities in electrophysiology through new launches, new data, and ambulatory surgery center expansion.

Boston Scientific Corporation (NYSE:BSX) develops and manufactures medical devices used in interventional medical specialties, including cardiology, endoscopy, urology, and neuromodulation. Its portfolio includes stents, catheters, implantable defibrillators, pacemakers, and devices for pain management and deep brain stimulation.

While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Foreign Stocks to Buy Right Now and 11 Best AI Penny Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.